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Abstract  
Background:  Every year Kentucky Children’s Hospital (KCH) admits infants and toddlers with 
respiratory disease due to viral bronchiolitis.  This disease is characterized by viral-induced 
inflammation and edema of the lower airways.  The resulting disease is characterized by 
increasing mucus production, acute bronchospasm, necrosis of the respiratory epithelium and 
functional obstructive lung disease.  Patients usually present with symptoms consistent with an 
upper respiratory tract infection, but can progress to marked respiratory distress and ultimately 
respiratory failure, as well as poor oral intake and dehydration.  While Respiratory Syncytial 
Virus (RSV) is the pathogen classically described cause of viral bronchiolitis, other viruses have 
been known to cause this pathophysiology and symptoms.  These viruses tend to cause disease 
during the colder months of the year, with a peak incidence between November and March.  
While there are no data regarding the disease burden for all viruses that can cause 
bronchiolitis, RSV infects approximately 90% of children in North America in the first two years 
of life with approximately half of those developing lower airway disease (Ralston, Lieberthal, & 
Meissner, 2015).   
 
In 2014, consensus clinical practice guidelines (CPG) regarding the outpatient and inpatient 
management of RSV bronchiolitis were published in Pediatrics.  These guidelines were 
published with the goal of standardizing care across the spectrum of clinical environments and 
avoid unnecessary and unwarranted therapies.  Currently, no specific treatment exists for this 
condition outside of supportive care, including invasive respiratory support ranging from 
supplemental oxygen to extracorporeal membrane oxygenation, IV hydration and airway 
clearance (Ralston et al., 2015).  The medical literature describes a cohort of patients who are 
more likely to require Pediatric Intensive Care Unit (PICU) admission and support with PICU 
modalities, which increases the likelihood of complications related to medical care (Haataja, 
2018).   
 
Objectives:  The aim of this project was to quantify and categorize the disease burden 
associated with viral bronchiolitis at KCH.  We examined all inpatient admissions of children ≤24 
months to KCH with the diagnosis of viral bronchiolitis during two peak incidence seasons, 
defined as beginning November 1 and ending April 30.  These admissions were evaluated based 
on the presence of significant co-morbid conditions and whether these conditions were 
associated with PICU admission.  The project also assessed resource utilization across the 
inpatient hospital and determined which patients received no low-value treatments or 
diagnostics.  These patients were defined as having received optimal care.   The study also 
examined high flow nasal cannula (HFNC) utilization across the inpatient ward and PICU, 
including number of cases at KCH, number of transfers to the PICU and number of patients 
requiring immediate escalation or de-escalation in care.    
 
Results:  A total of 601 admissions for viral bronchiolitis were identified between the dates of 
peak incidence season, including 281 admissions between November 1, 2016 and April 30, 2017 
as well as 320 admissions between November 1, 2017 and April 30, 2018.  A total of 186 
admissions were identified in which the patient had a history of prematurity and 37 admissions 
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in which the patient had congenital heart disease (CHD).  Other co-morbidities like 
neuromuscular disease, immunodeficiency and tracheostomy with or without chronic 
mechanical ventilation were identified only in small numbers.  The mean age at admission was 
6.37 months (median 3.75 months) old with a median admission weight of 6.5 kg.  The age and 
weight distribution was skewed towards younger patients.  Average length of stay was 100.43 
hours with an overall cost of almost $3.9 million to the institution for all admissions.  Most 
admissions come through the KCH Pediatric Emergency Department (PED) but a larger 
proportion of patients came to KCH via transfers from community hospitals within the region.  
Bronchiolitis appeared to drive hospital capacity in the first four months of the season but 
appeared to contribute less in March and April.  Prematurity and CHD were associated with 
Pediatric Intensive Care Unit (PICU) admission (p=0.003, p=0.032) and higher total hospital 
costs (p=0.012, p=0.028).  Premature patients had a higher overall utilization of bronchodilator 
therapy (p<0.001), systemic corticosteroids (p<0.001), radiograph utilization (p=0.015) and viral 
testing (p=0.007) but no significant differences in antibiotic use compared to the rest of the 
patients (p=0.705).  Patient with CHD had a higher overall utilization of bronchodilators 
(p=0.007), radiograph utilization (p=0.001) and viral testing (p<0.001) with no significant 
differences in antibiotic use (p=0.61) or corticosteroid use (p=0.051) compared with the rest of 
the patients.  Utilization overall was more likely for PICU patients in all five metrics.  Patients 
with no co-morbid conditions were considered to be optimal care candidates with patients who 
received no diagnostic and therapeutic intervention were considered to have received optimal 
care.  Utilization in optimal care candidates versus patients who were not candidates from 
optimal care was significantly different in every metric except antibiotics among the 2017-18 
cohort and not significantly different in every metric among the 2016-17 cohort.  The 
proportion of patients who received optimal care increased from 32.1% in 2016-17 to 34.7% in 
2017-18.  A total of 167 admissions were placed on the therapy, of which 106 were started on 
HFNC on the inpatient ward and 60 in the PICU.  Of those started on HFNC on the inpatient 
ward, transfers to the PICU decreased from 65% in 2016-17 to 41% in 2017-18.  Of the 51 
patients transferred to the PICU, seven (13.7%) were transferred back to the ward within 24 
hours, six (11.7%) were escalated to non-invasive positive pressure ventilation (NIPPV) within 
12 hours and another five (9.8%) were intubated and placed on mechanical ventilation within 
12 hours.   
 
Discussion and Conclusions:  This analysis suggests that most of the utilization of resources and 
costs associated with inpatient care for bronchiolitis are diverted towards patients with 
significant co-morbid conditions and patients who require PICU admission.  The ultimate goal 
will be to reduce resource utilization among optimal care patients and increase the proportion 
of patients needing fewer interventions.  This will include annual data collection prospectively 
for each peak incidence season and an annual scorecard to present at institutional quality and 
safety (Q&S) meetings.  A KCH respiratory work group has been formed to help create 
educational materials for KCH providers and staff on the correct assessment of an infant or 
toddler with respiratory distress as well as a review of the recent CPG.  The work group will also 
provide outreach education to community and rural healthcare providers who may have limited 
experience in the care of pediatric patients.  Data from county of origin will help direct this 
education to areas that send a larger volume of patients with bronchiolitis to KCH in order to 
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optimize the impact.  Multiple peak incidence seasons of inpatient data will help inform the 
creation of a new bronchiolitis protocol to guide inpatient management at KCH.  HFNC data will 
continue to be collected during future peak incidence seasons in order to identify patient 
escalations, limit unnecessary transfers of patients to the PICU, and determine how KCH can 
best manage patients on HFNC outside of the PICU.  The work group will also revise an existing 
HFNC management protocol in line with recent medical literature.  Lastly, the work group will 
incorporate the KCH Pediatric Emergency Department (PED) and outpatient pediatric clinics in 
order to create an integrated project that spans the entire continuum of care.    The project also 
fills a critical role in promoting best practices not only in the hospital, but within the 
community.  KCH can play a leading role in promoting a competent, educated workforce both in 
the hospital and in the community.  The hospital can also use the data to identify deficiencies 
both within the hospital and in the rural areas of Kentucky and create strategies to address 
them.   
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Introduction 
Bronchiolitis is a condition caused by viral infection, traditionally with a virus called 
Respiratory Syncytial Virus (RSV).  This disease commonly affects infants and toddlers by 
causing inflammation and edema of the lower airways.  The disease pathology results in 
increased mucus production with associated bronchospasm, necrosis of the respiratory 
epithelium and functional obstructive lung disease (Kliegman, 2007).  Patients usually present 
initially with symptoms consistent with an upper respiratory tract infection, but can progress 
over several days toward marked respiratory distress and ultimately respiratory failure as well 
as poor oral intake resulting in dehydration.  This is due to progression of lower airway disease 
from mucus plugging in the medium sized lower airways, or bronchioles (Zitelli, 2002).  In this 
way, it mimics a condition like asthma, with inflammation and acute bronchospasm of the 
medium sized bronchioles.  Infants with bronchiolitis can present with nasal congestion and 
cough, but can quickly develop wheezing, rales, tachypnea and other signs of respiratory 
distress.  Some infants require advanced respiratory support, via either high flow nasal cannula 
(HFNC), mechanical ventilation or even extracorporeal membrane oxygenation (ECMO).   
RSV is the most frequent cause of bronchiolitis in infants and toddlers, accounting for 
125,000 hospitalizations and 250 infant mortalities in the United States annually (Piedimonte & 
Perez, 2014).  Approximately 90% of children in North America are infected with RSV at some 
point in the first two years of life with approximately half of those developing lower airway 
disease (Ralston et al., 2015).  The hospitalization in the United States rate is 5.2 per 1000 
children less than 2 years old with a healthcare cost of over $1.7 billion dollars annually (Ralston 
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et al., 2015). The World Health Organization (WHO) estimates that RSV bronchiolitis accounts 
for more than 60% of all acute respiratory infections in children and over 80% of acute 
respiratory infections in infants less than one year of age (Piedimonte & Perez, 2014).  The 
incidence of hospitalization is higher among infants under 60 days old (25.9 per 1000 children) 
and among premature infants under 30 weeks gestational age (18.7 per 1000 children)          
(Ralston et al., 2015).   
Over the past decade, with the advent of direct fluorescent antibody and polymerase 
chain reaction (PCR) testing, pediatricians have been able to identify multiple different viruses 
that can cause bronchiolitis, including enterovirus, adenovirus, human metapneumovirus and 
others (Kliegman, 2007).  There is no clear, compelling data regarding the disease burden for all 
viruses that can cause bronchiolitis, only for RSV, nor is there evidence that any particular virus 
causes a more serious infection (Ralston et al., 2015).  This might suggest that the total burden 
of bronchiolitis as a disease, including non-RSV infections, is likely underestimated.  These 
infections tend to have a peak incidence season during colder months, particularly between 
November and April in the United States, however they can be year-round in subtropical 
environments seen in places like Florida (Figure 1) (Ralston et al., 2015).   
In 2014, a consensus clinical practice guideline (CPG) regarding the outpatient and 
inpatient management of bronchiolitis was published in Pediatrics.  These guidelines stressed 
that bronchiolitis was primarily a clinical diagnosis, meaning that the diagnosis could be made 
based on clinical suspicion due to signs and symptoms and the patient’s age (Ralston et al., 
2015).  Therefore, viral testing was deemed unnecessary and management of the disease was 
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the same regardless of the viral etiology.  The guidelines were also published with the goal of 
establishing a standard of care across the spectrum of clinical environments.   Currently, no 
specific treatment exists for this condition outside of supportive care, including invasive 
respiratory support ranging from supplemental oxygen to ECMO, intravenous (IV) hydration 
and airway clearance via nasal suctioning (Piedimonte & Perez, 2014).  The goal of supportive 
care is to keep the patient appropriately hydrated and avoid hypoxia.  Treatments such as 
inhaled bronchodilators, systemic corticosteroids and antibiotics have previously been 
considered as possible therapeutic interventions.  However, the guidelines explicitly 
recommend against the use of these therapeutics, concluding that they have minimal benefit in 
the treatment of bronchiolitis (Zorc & Hall, 2010); (King et al., 2004).  Similarly, the guidelines 
recommend against obtaining diagnostic chest radiographs as x-rays do not change 
management of the disease and expose children unnecessarily to radiation (Zorc & Hall, 2010).   
The medical literature describes a cohort of patients who are more likely to require 
Pediatric Intensive Care Unit (PICU) admission.  These patients include ones with a history of 
prematurity, congenital heart disease (CHD), immunodeficiency, neuromuscular disease or 
patients with chronic respiratory failure requiring tracheostomy with or without chronic 
mechanical ventilation (Haataja et al., 2018); (Ralston et al., 2015).  These patients may require 
more invasive respiratory support including HFNC, mechanical ventilation and ECMO.  This in 
turn may lead to patients receiving other ancillary interventions, such as the above listed 
diagnostic and therapeutic modalities, as well as urinary catheter placement or central venous 
catheter placement.  Support with these types of interventions increases the likelihood of 
iatrogenic complications related to medical care.  The 2014 CPG excludes patients admitted to 
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the hospital with any of these co-morbid medical conditions and those admitted to the PICU 
(Ralston et al., 2015).  Therefore, patients excluded from the CPG are considered to be 
potential outliers who may need more aggressive care, including some of the treatment 
modalities that are considered low-value in bronchiolitis patients without significant co-
morbidities.  While there have been recent studies demonstrating the safety of HFNC outside of 
the PICU, its overall efficacy and specific titration parameters remain unclear and are often 
dependent on institutional practices (Franklin et al., 2018); (Kepreotes et al., 2017).   
In order to reduce the use of these treatments and diagnostics in otherwise healthy 
infants with bronchiolitis, a collaborative quality improvement (QI) project used educational 
tools to reduce the use of low value therapies and diagnostic studies in treating infants and 
toddlers with viral bronchiolitis.  Of the 21 centers that participated in the project, most 
identified as pediatric units within a larger hospital.  With staff education, these centers were 
able to collectively reduce average bronchodilator use by 29%, reduce steroid use by 68%, 
reduce chest radiography use by 44% and noted a decreased hospital length of stay by five 
hours (Ralston et al., 2016).  This QI project demonstrated that educational and outreach 
strategies can be employed to reduce utilization of resources for patients with viral 
bronchiolitis in the children’s hospital and can be applicable to children’s hospitals globally 
(Figure 2) (Ralston et al., 2016).  In the United Kingdom, the National Institute for Health and 
Care Excellence (NICE) has implemented similar educational strategies and guidelines for care in 
the management of bronchiolitis and have seen compliance with the NICE guideline increase 
from 28% in its first year to 63% within 3 years (Breakell, Thorndyke, Clennett, & Harkensee, 
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2018).  Patients who did not receive any of the described treatments or diagnostic studies are 
considered to have received optimal care in accordance with the CPG.  
Present Study 
Each year Kentucky Children’s Hospital (KCH) admits infants and toddlers with 
respiratory disease due to bronchiolitis.  These patients are admitted from locations throughout 
the Commonwealth of Kentucky and surrounding region.  Many of these patients first come to 
medical attention in outpatient clinics, urgent care centers, community-based emergency 
departments (ED) or the KCH pediatric emergency department (PED).  The clinical disease 
burden associated with bronchiolitis at KCH has been unclear.  Along with the lack of 
knowledge of the demographics of this patient population, KCH has no recent data on 
utilization of therapeutic interventions such as bronchodilators, systemic corticosteroids, HFNC 
or antibiotics.  Similarly, KCH has no recent data regarding utilization of diagnostic modalities 
like radiography and viral testing.  While KCH created a HFNC protocol in 2013, it does not 
account for the new clinical guidelines or recently published studies outlining titration 
strategies or efficacy as no real true best practices exist (Miller, Gentle, Tyler, & Napolitano, 
2018).  
This project aimed to quantify the disease burden associated with bronchiolitis at KCH.    
This included identification of the sex, weight and age demographics of patients being admitted 
to KCH, co-morbid conditions of patients admitted with bronchiolitis, and utilization of low-
value diagnostic and therapeutic interventions specifically discussed in the 2014 CPG.  This 
study also benchmarked admissions against hospital capacity and evaluated total cost to the 
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institution.  The data collected in this study will inform the design and implementation of 
educational outreach to outlying rural communities that transfer patients to KCH as well as 
institutional education on the published CPG.   
Methods 
The core research group obtained approval from the Institutional Review Board (IRB) to 
collect retrospective data from the two most recent peak incidence seasons.  Peak incidence 
season was defined as beginning on November 1 and ending April 30.  Our team met with data 
analysts from the Office of Value & Innovation in Healthcare Delivery (OVIHD) to help obtain the 
data.  The inclusion criteria were any child ≤24 months of age admitted to KCH with the diagnosis 
of viral bronchiolitis between November 1, 2016 and April 30, 2017 (represented as 2016-17), 
and between November 1, 2017 and April 30, 2018 (represented as 2017-18).  All data were from 
the patient electronic medical record (EMR).  Admissions for bronchiolitis were identified by 
admit ICD-10 diagnosis codes for viral bronchiolitis, viral respiratory disease or viral pneumonia.  
These patients were then screened for prematurity, CHD, neuromuscular disease, 
immunodeficiency, having a tracheostomy, and having a tracheostomy along with ventilator 
dependence.  These conditions were also identified by International Classification of Diseases 
(ICD-10) diagnosis codes, but also by performing multiple keyword searches in the admission 
History and Physical (H&P) for common phrases to describe prematurity and for diagnosis-
specific CHD, immunodeficiencies and neuromuscular diseases.  Patient sex, as well as admission 
weight and age were also pulled directly from the patient chart flowsheets.  Bronchodilator and 
steroid use were determined by search for physician orders for these medications as well as 
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presence in the medication administration record (MAR).  Comprehensive respiratory panels are 
used as diagnostic testing at KCH to identify the specific viral nucleic acids in nasopharyngeal 
secretions.  The use of this test was identified by physician order and results obtained in the EMR.  
Admissions where chest radiography was performed were similarly identified by the presence of 
a physician order as well as a result posted in the EMR.  To assess antibiotic usage, we identified 
patients who received antibiotics by physician order in the EMR, then searched all patients for 
secondary infections, including ICD-10 codes for pneumonia, urinary tract infection (UTI), otitis 
media, bacteremia, meningitis and tracheitis.  Patients who received these antibiotics with these 
concomitant bacterial infections were considered to have appropriate use of antibiotics and were 
not considered as part of resource utilization for this metric.  Admissions where patients without 
comorbidities received none of these treatments were considered to have received “optimal 
care” under the current CPG.  Downstream PICU utilization metrics such as urinary catheter 
placement, central venous catheter (CVC) placement, escalation to non-invasive positive 
pressure ventilation (NIPPV) or mechanical ventilation were obtained by data analysts looking at 
EMR flowsheets and procedure notes.  HFNC data were obtained through respiratory therapist 
orders and respiratory care flowsheets in the EMR.  Total hospital costs and hospital length of 
stay were obtained by data analysts through the UK data warehouse and the Integrated Business 
Unit (IBU).  Hospital capacity data for 2017-2018 was provided by the KCH Quality and Safety 
(Q&S) Committee.   
 Statistical analyses were performed by the principal investigator using IBM SPSS™ with 
assistance from the dedicated University of Kentucky (UK) Department of Pediatrics 
biostatistician.  The data were described using descriptive statistics such as frequencies and 
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percentages.  Age, weight, length of stay and hospital costs were represented as median, mean, 
standard deviation and interquartile range.  Admissions to UK were listed as frequency by 
location or point of origin.  Comparison of co-morbid condition and PICU admission was 
performed using Chi-square analysis.  Comparison of comorbid cohorts and length of stay and 
hospital costs were performed using analysis of variance (ANOVA) and non-parametric testing.  
Comparison of resource utilization between candidates for optimal care and non-candidates was 
performed using Chi-square analysis.   
Results 
 Basic demographics  
The data obtained yielded 601 admissions in both years, including 281 involving 259 
patients in 2016-17 and 320 admissions involving 300 patients in 2017-18.  Both years 
demonstrated a male predominance (55.9% and 59.7% of admissions, respectively (table 1).    The 
mean age at admission was 6.37 and 6.05 months respectively with a median of 3.75 and 3.7 
months (table2).  This demonstrated a rightward skew on the distribution of admissions by age 
(figure 3), suggesting more admissions for children of younger age.  Admission weight showed a 
less skewed distribution and difference between mean and median (table 2, figure 4).   Mean 
length of stay was 100 hours in 2016-17 and 118 hours in 2017-18 (table 3).  Average admission 
costs were $5,725.62 per patient with a total institutional cost of $1.61 million in 2016-17 and 
$7,053.55 per patient with a total cost $2.26 million in 2017-2018 (table 4).  Therefore, the total 
hospital cost for the care of all inpatients at KCH was nearly $3.9 million dollars for both years 
combined.   
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 A linear regression analysis showed a significant negative relationship between age and 
length of stay, with longer stays associated with younger age after removal of significant outliers 
greater than three standard deviations above the mean length of stay (R= -0.11, p=0.003) (figure 
5).   The negative relationship between length of stay and weight was even stronger (R= -0.19, 
p<0.001) (figure 6).   
 Admissions to KCH 
 When examining throughput into KCH, most admissions in both years (85.1% and 89.4%) 
were admitted through the KCH PED, with smaller numbers being directly admitted from an 
outside institution or clinic (figure 7).  Looking at admissions through the PED specifically, both 
years showed differences in how they arrived in the ED.  In 2016-17, 61.5% of PED admissions 
came to the PED from the community or a non-healthcare origin versus 40.2% in 2017-18.  Overall 
2017-18 shows more balance between patients that arrived from the community, versus patients 
transferred to the KCH PED from an outside institution or clinic/office (figure 8).  Of all 
bronchiolitis admissions to KCH during both peak incidence seasons, 26.2% came from Fayette 
County with another 19.8% coming from the immediate neighboring counties: Scott, Bourbon, 
Clark, Madison, Jessamine and Woodford (figure 9).  Heat maps, broken down by year also 
demonstrate an increasing number of admissions originating along the Interstate-75 corridor to 
the south of Lexington, especially Laurel, Knox and Whitley counties (figure 10).   During the 2017-
18 season, bronchiolitis admits rose and fell proportionally with the percentage of days KCH was 
above maximum bed capacity for November through February.  However, for March and April, 
percent days above capacity rose despite decreases in bronchiolitis admissions, suggesting that 
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the correlation falls off toward the end of the peak incidence season and other conditions 
account for the KCH inpatient census (figure 11).    
 Co-morbid conditions 
 The data search yielded 186 premature patients admitted to KCH with bronchiolitis.  We 
stratified these patients by season and by degree of prematurity.  In 2016-17, 21% of admissions 
(n=59) were identified as being between 31 and 36 weeks gestational age (GA) and 6.8% of 
admissions (n=19) 30 weeks GA or under.  In 2017-18, 21.6% of admissions (n=69) were identified 
between 31 and 36 weeks GA and 12.2% of admissions (n=39) were 30 weeks GA or under (figure 
12).  Thirty-seven patients were identified with CHD, with the specific type of disease shown here 
(figure 13).  The most frequent types of CHD are ventricular septal defects (VSD n=9), atrial septal 
defects (ASD n=6) and Tetralogy of Fallot (TOF n=5).  Premature patients overall were more likely 
to require admission to the PICU compared to non-premature patients (p=0.003).  Patients with 
CHD were similarly more likely to require PICU admission (p=0.032) (table 5).  Our population 
search yielded low numbers of admissions with tracheostomy (n=5), tracheostomy with 
ventilator dependence (n=2) and immunodeficiency (n=5) so statistical analysis was deferred on 
these admissions.  Immunodeficiency diagnoses included two admissions of patients with 22q11 
deletion and three admissions of the same patient with α-1 antitrypsin deficiency.  No patients 
with neuromuscular disease were admitted in either season.  Using one-way ANOVA, there were 
significant differences in mean length of stay between infants and toddlers born at term, born 
between 31 and 36 weeks GA and born at or before 30 weeks GA (p=0.002) (table 6).  This analysis 
was performed after removing significant outliers greater than three standard deviations beyond 
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the mean.  Post hoc analysis shows a significant difference between length of stay of term 
children versus premature children ≤30 weeks GA (p=0.01).  The difference in length of stay 
between term children versus children 31 and 36 weeks GA was not statistically significant 
(p=0.058).  There are also significant differences between each range of prematurity in terms of 
hospital costs as well (p=0.012) but no significant differences in PICU costs (p=0.08) (table 7).   
Admissions with CHD do not have significant differences in length of stay compared to admissions 
who do not have CHD (p=0.063).  However, total hospital costs are significantly higher in patients 
with CHD (p=0.028) with no significant differences in PICU costs (p=0.419) (figure 14, table 8).   
 Resource utilization 
 Part of the analysis with resource utilization includes identification of use in the entire 
cohort as well as a subgroup that has no comorbid conditions or risk factors that would prompt 
exclusion based on the CPG.  Patients without co-morbid conditions were considered optimal 
care candidates.  These patients truly received optimal care if they did not get any of the two 
diagnostic studies or the three therapeutic interventions.  Data analysis identified 193 candidates 
in 2016-17 and 199 candidates in 2017-18 for bronchiolitis optimal care, meaning they received 
none of the five diagnostic and therapeutic interventions specifically discussed in the CPG.  Our 
analysis looked at bronchodilator use, systemic corticosteroid use, antibiotic use, chest 
radiograph use and viral testing use.   
 We identified 148 admissions where bronchodilators were administered.  This includes 
65 admissions in 2016-17 and 83 admissions in 2017-18.  The overall gross utilization was 24.6% 
of all admissions.  Patient received anywhere from one to 23 doses.  More doses were associated 
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with a longer length of stay and increased hospital costs (p<0.001 for both) (figure 15).  However, 
utilization and number of doses went down among the optimal care cohort (figure 15).  
Bronchodilator utilization among optimal care candidates was 19.9% for both seasons combined 
(20.2% in 2016-17 and 19.6% in 2017-18).  When comparing bronchodilator utilization between 
optimal care candidates and the rest of the patients, utilization was significantly different in the 
2017-18 season (p=0.001) and overall across both seasons (p<0.001), and not significantly 
different in 2016-17 (p=0.085) (table 9).  When comparing bronchodilator use between optimal 
care candidates and premature patients and between patients with CHD, utilization in both 
groups with co-morbid conditions was higher (36%; p<0.001, 32.4%; p<0.001).  Statistical analysis 
yielded similar findings for corticosteroid use, where we identified an overall utilization of 16.8% 
(20.7% in 2016-17 and 13.1% in 2017-2018).  Steroid use among the optimal care cohort in 2016-
17 was not significantly different when compared to the remaining patients (p=0.313) but was 
significantly different in 2017-18 (p<0.001) and overall (p<0.001) (table 10).  Comparison of 
corticosteroid utilization among optimal care candidates with premature infants shows 
significantly higher utilization among the premature group (32.8%, p<0.001).  A comparison of 
corticosteroid utilization between optimal care candidates and CHD approached statistical 
significance (29.7%; p=0.051).  A total of 209 patients received antibiotics in both seasons for a 
gross utilization of 34.7%.  However only 111 of optimal care candidates received antibiotics but 
did not have an identifiable bacterial infection.  A total of 120 infections were identified in 98 
patients.  Infections identified include a large proportion of bacterial pneumonia and otitis media 
(figure 16).  After removing patients with bacterial infections, a utilization rate overall of 21.9% 
was calculated.  When optimal care candidates were compared to the remaining cohort as well 
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as to premature patients (23.9%; p=0.71) and patients with CHD (17.9%; p=0.61), no significant 
differences were noted, suggesting that antibiotic use was similar across the different co-morbid 
groups (table 11).   
 Similar analyses were performed for chest radiograph utilization and for viral testing.  A 
total of 299 patients received chest radiographs with a gross utilization of 49.7%.  Within the 
optimal care group, total utilization was 45.7%.  Utilization between optimal care candidates and 
the rest of the cohort was significantly different overall (p=0.006) and in 2017-18 (p=0.007) but 
not significant in 2016-17 (p=0.292).  Utilization between optimal care candidates and premature 
and CHD patients is statistically significant (56.5%, p=0.015; 73%, p=0.001) (table 12).  Viral panel 
testing yielded multiple viruses isolated in children with viral bronchiolitis.  In 2016-17, 82 viral 
tests were performed with 114 viruses identified (figure 17), while in 2017-18 110 viral tests with 
126 viruses identified (figure 18).  RSV was the most commonly isolated virus with 
rhinovirus/enterovirus also being identified frequently.  Utilization among optimal care 
candidates was 29.1% overall (29.5% in 2016-17 and 28.6% in 2017-18).  Compared to the 
remaining cohort, there was significantly lower utilization in optimal care patients overall 
(p=0.004) and in 2017-18 (p=0.006), with no significant differences in utilization between groups 
in 2016-17 (p=0.254) (table 13).          
 PICU and HFNC data 
   A total of 168 admissions in both seasons to the PICU were identified.  Of those, 101 were 
initially admitted to the PICU and 67 were initially admitted to the pediatric ward and ultimately 
transferred to the PICU for presumably worsening status (table 14).  Of these 168 admissions, 20 
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patients required escalation to NIPPV for respiratory support, 47 required intubation and 
mechanical ventilation.  Ten patients were placed on both modalities.  Patients had longer 
lengths of time on mechanical ventilation with increasing age (R=0.39, p=0.007) (Figure 19).  
Patients with prematurity and CHD were more likely to have PICU admission compared to 
patients without those co-morbidities (p=0.003, p=0.032) (table 15).   Overall PICU admissions 
had higher rates of utilization than non-PICU admissions across the board in all five resource 
utilization metrics (figure 20).   
 HFNC use was identified in 166 patients in both seasons.  A total of 22.8% of admissions 
in 2016-17 and 31.9% in 2017-18 were placed on HFNC.  Approximately two-thirds of these 
patients were initially admitted to the inpatient ward while the remaining one-third were 
admitted to the PICU.  Of the patients on HFNC admitted to the inpatient ward, 65% in 2016-17 
and 41% in 2017-18 ultimately required transfer to the PICU.  A total of 19% and 7.4% of these 
PICU transfers in each season tolerated de-escalation of care and were able to transfer back to 
the inpatient ward within 24 hours.  However 6 patients (11.3%) total in both seasons required 
escalation to NIPPV within 12 hours and 5 patients (9.4%) were intubated and placed on 
mechanical ventilation within 12 hours (figure 21).  The mean length of stay, time on HFNC or 
hospital costs for patients on HFNC were not significantly different whether patients were 
admitted to the PICU or ward initially (table 16).   
Discussion 
 Bronchiolitis epidemiology 
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Bronchiolitis is a very common disease in infants and toddlers, and providing the 
appropriate standard of care reduces iatrogenic complications from treatments and diagnostics, 
reduces family confusion with disease course and treatment and can reduce costs for the 
institution, families and insurance companies (Mussman et al., 2018).  In order to reduce costs 
related to unnecessary care, multiple institutions have implemented an optimal care model, 
which tracks utilization of resources and identifies patients who have received appropriate care 
(Ralston et al., 2016).  In order to achieve this goal at KCH, the appropriate patient population 
must be identified and education be provided to KCH staff as well as emergency medical service 
(EMS) providers and community ED providers who ultimately transfer patients to KCH for 
inpatient care.  These data identify the total number of admissions at KCH for two peak incidence 
seasons, as well as where in the Commonwealth of Kentucky these admissions came from.  The 
data also demonstrated that the KCH PED and was the primary point of entry into the hospital 
and therefore is often the first location to provide medical care for children with bronchiolitis.  
UK pediatric clinics affiliated with UK and KCH also serve as a first location at which care was 
provided.  Therefore including the PED and UK pediatric clinics in an ongoing project will be 
necessary as the standard of care can be established at the initial location where care is provided.  
The PED and UK pediatric clinics are also a critical source of data as both practice settings serve 
as a filter for patients into the hospital, while discharging others home without inpatient 
admission.  Any further analysis of resource utilization for bronchiolitis patients at KCH must 
include both the PED and UK pediatric clinic system.  Inclusion of these practices will allow the 
institution to provide a critical public health service of educating the affected population, in this 
case families of children with bronchiolitis, on how to properly care for children with this disease 
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as well as develop strategies that support patient families who caring for children with 
bronchiolitis (CDC, 2018).   
The data on county of origin demonstrated that slightly less than half of bronchiolitis 
admissions came from Fayette County and the immediate surrounding counties.  This means that 
over half of admissions came from more distant counties that have EMS and community ED 
personnel with limited experience in the care of pediatric patients.  Knowing the distribution of 
counties where admissions to KCH originate informs how the institution can provide outreach 
and education to these providers.  This is especially true of counties to the southeast of Lexington, 
which can be very remote from Interstates 75 or 64.  Therefore, these counties may not have the 
immediate capability to promptly transfer patients from their community health care facilities to 
KCH, and therefore will have to shoulder the burden of an initial assessment and stabilization of 
these patients.  KCH has a critical public health role in helping train competent public and 
personal healthcare workforce to care for children with bronchiolitis, and serving as a resource 
to improve the effectiveness, accessibility and quality of care provided at these outside 
institutions (CDC, 2018).  Experienced providers from KCH ought to serve in a leading role in the 
education of rural community providers in how to care for bronchiolitis patients.  This includes 
initial assessment of an infant or child in respiratory distress and a thorough review of the CPG.  
The PED also has a role in providing guidance away from low value therapies to outside 
institutions when they call for transfer.   
 Resource Utilization at KCH 
 Analysis of the data suggests that the bulk of resource utilization goes toward patients 
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with significant co-morbid conditions such as prematurity and congenital heart disease.  
Resource utilization is also directed toward patients admitted to the PICU as well, and the data 
suggests that the presence of co-morbidities makes PICU admission more likely.  Of the patients 
without co-morbidities, there appears to be less overall utilization in 2017-18 versus 2016-17.  
The overall number of patients who received true optimal care was 32.1% of candidates in 2016-
17 and 34.7% in 2017-18.  The highest utilization overall appears to be chest radiography at 46.6% 
and 44.7% in each year (figure 22).  The lowest overall utilization appears to be steroids at 20.7% 
and 13.1% each year (figure 22).  Future directions suggest these utilization rates can be 
benchmarked against comparable institutions in order to establish the opportunity for 
improvement (S. Ralston, Parikh, & Goodman, 2015).    Therefore, educational material for KCH 
pediatric providers, nurses and staff is also critical.  This includes a thorough review of the CPG, 
as well as review of proper nasal suctioning technique, and proper assessment of bronchiolitis 
patients for signs of deterioration.  These signs include worsening work of breathing, hypoxia and 
dehydration.  Along with education, creation of a bronchiolitis protocol to standardize care for 
all patients will be essential for inpatients at KCH going forward.  Comparison of resource 
utilization during peak incidence and non-peak incidence seasons may help determine which 
resources are used more in the winter when hospital census due to viral bronchiolitis tends to be 
highest and inform the institution on what staff, equipment and other resources need to be 
available at specific times of the year. (Mittal et al., 2014)     
 HFNC use at KCH 
 HFNC use in patients with viral bronchiolitis remains a challenge to KCH as there are no 
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clear guidelines on its efficacy or use.  While HFNC has long been considered a PICU modality, its 
safety for use outside of the PICU has been demonstrated at other institutions (Franklin et al., 
2018); (Kepreotes et al., 2017).  Tracking admissions on HFNC to the PICU versus inpatient ward 
may be helpful in identifying deficits and strengths in the institution’s overall investment in 
resources and training for staff.  Tracking escalation and de-escalation metrics will be useful.  
Escalation metrics include patients started on HFNC on the inpatient ward and subsequently 
transferred to the PICU for more aggressive care and patients requiring escalation to NIPPV or 
mechanical ventilation within four hours and 12 hours.  Patients requiring intubation within one 
hour of arrival to the PICU suggest an actively decompensating patient and require individual 
root cause analysis to determine what signs of worsening respiratory failure were missed on the 
ward.  The de-escalation metrics to track include transfer back from the PICU to the inpatient 
ward within 24 hours, which suggests that the patient was able to come off HFNC quickly and 
may suggest overly aggressive titration of flow and oxygen levels of outside of the PICU.   Along 
with summary review of these metrics, education to a specific cohort of the KCH nursing and 
respiratory therapy (RT) staff selected to take care of patients with viral bronchiolitis during peak 
incidence season may improve nursing and RT comfort with assessing respiratory distress and 
would potentially prevent unnecessary escalation and identify children who are truly getting 
worse and need transfer to the PICU.  Such information could inform KCH to create a respiratory 
ward during peak incidence season, so that all respiratory patients are close together in 
proximity.  This will help reduce the times between assessments by trained providers and staff.  
This will help especially after hours, when resident physician providers and RT staff are primarily 
responsible for serial assessments of these patients.   These future directions fulfill a public health 
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service of creating policies within the largest children’s hospital in this region to support these 
patients in the safest and most effective way.  An institution like KCH being heavily involved in 
bronchiolitis education and outreach both in and outside of the hospital, outpatient clinics, PED, 
EMS first-responders and outlying community institutions can also empower stakeholders to 
advocate for resources for these patients, both within the public health infrastructure but also 
advocate for policy changes at the state and local governmental level (CDC, 2018).   
 The KCH Respiratory Work Group  
 In conclusion, review of these data as well as future prospective data collection can have 
major implications on the management of bronchiolitis at KCH.  While the retrospective data 
collected was important for identifying baseline demographics, co-morbidities and origin of 
patients, continuous data collection per peak incidence season will be essential for ongoing QI in 
order to further streamline care.  An IRB application is currently being written to perform yearly 
data collection prospectively.  This data will be reported annually at KCH Q&S meeting.  In order 
to ensure ongoing success of this project, the KCH respiratory work group was formed in 2017 
and consists of physicians, nurses and respiratory therapists employed at UK and KCH.  The work 
group has multiple roles within KCH in regards to respiratory care for hospitalized children.  One 
of the goals of the work group will be to provide didactic education, develop web-based modules 
for staff education and to collect and present data for each peak incidence season in regards to 
bronchiolitis.  The work group will also lead outreach education to community partners.  
 In order to ensure this ongoing project covers all areas with care, physician champions 
from the PED as well as UK outpatient pediatric clinics will join the work group and participate in 
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ongoing data collection and education in their respective clinical areas as well as outreach to 
community providers.  Along with education for the community and KCH staff, the work group 
will also be responsible for the creation and revisions of a KCH viral bronchiolitis protocol with 
the goal of streamlining and standardizing management across different locations within the 
hospital.   The work group has also been tasked to revise an existing HFNC based on the most up 
to date literature and track escalation and de-escalation metrics.  
To determine which metrics are important the work group created the viral bronchiolitis 
seasonal scorecard (figure 23).  This will serve as an easy reference to look at resource utilization 
among optimal care candidates and HFNC metrics.  Benchmarks will need to be created based on 
data from comparable outside institutions involved in the AAP Bronchiolitis Quality Improvement 
Project as well as an achievable benchmark of care derived from our retrospective institutional 
data (Mittal et al., 2014).  HFNC benchmarks will be set based on institutional data since no 
national benchmarks exist.  The respiratory work group will be responsible for creating and 
maintaining the scorecard through each peak incidence season.  The work group will also 
consider other metrics, such as time to initiation of enteral feeding, feeding tube placement and 
the incorporation of bronchiolitis scoring into regular assessments.  These interventions can 
make KCH a community and national leader in the care of infants and toddlers with bronchiolitis 
and can serve as a potential model for other institutions throughout the country and world.   
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Figure 2 
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Table 1
 
Bronchiolitis Admissions to KCH by Sex 
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Table 2 
 
Bronchiolitis admission descriptives:  Age (in months) and Weight (in Kg) 
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Figure 3 
 
Histogram with frequency of admissions by age (in months) in 2016-2017 and 2017-2018 
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Figure 4 
 
Histogram with frequency of admissions by age (in months) in 2016-2017 and 2017-2018 
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Table 3 
 
Length of stay (in days and hours) by season  
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Table 4 
 
Total direct costs per admission and total. PICU direct costs per admission and total.    
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Figure 5 
 
Linear regression of length of stay (in hours) and age (in months).  N=589 with outliers >3 standard deviations 
for length of stay excluded.  (r=-0.11, p=0.003) 
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Figure 6 
 
Linear regression of length of stay (in hours) and weight (in Kg).  N=589 with outliers >3 standard deviation for 
length of stay excluded (r=-0.193, p<0.001) 
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Figure 7 
 
Admissions to KCH for vial bronchiolitis (PED vs outside institution) 2016-17 and 2017-18 
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Figure 8 
 
Admissions into KCH through the UK PED (2016-17 and 2017-18) 
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Figure 9 
 
Heat map of admissions by Kentucky County  
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Figure 10 
 
 
 
Heat map of Admissions by County by season (2016-17 and 2017-18) 
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Figure 11 
 
Bronchiolitis admissions by month with percentage of days per month over 100% hospital capacity 
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Figure 12 
 
Number of Admissions per year by prematurity:  Term (≥37 weeks GA), Late term premature (31-36 weeks GA), 
Severe prematurity (≤30 weeks GA) 
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Figure 13 
 
Congenital Heart Disease by diagnosis in patients with bronchiolitis 
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Table 5 
 
Prematurity and PICU admission  
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Table 6 
 
Length of stay by degree of prematurity 
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Table 7 
 
Total Hospital Costs and PICU direct costs by degree of prematurity 
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Figure 14 
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Table 8 
 
 
 
 
53 
 
Figure 15
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Figure 15 (continued) 
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Table 9 
 
Optimal Care candidates and bronchodilator use 
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Table 10 
 
Optimal Care Candidates and systemic corticosteroid use 
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Figure 16 
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Table 11 
 
Optimal Care Candidates and antibiotic use 
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Figure 17 
 
 
 
60 
 
Figure 18
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Table 12 
 
Optimal Care candidates and radiograph use  
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Table 13 
 
Optimal care candidates and respiratory panel testing 
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Table 14 
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Table 15 
 
Prematurity and congenital heart disease and PICU admission 
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Figure 19 
  
Linear regression of hours on mechanical ventilation and age (in months) (r=.388, p=.007) 
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Figure 20 
 
 
67 
 
Figure 21 
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Figure 21 (continued) 
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Table 16 
 
Length of stay on ward vs PICU and total hospital costs + PICU costs for patients on HFNC 
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Figure 22
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Figure 23 
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